Accra [Ghana]/ Mumbai (Maharashtra) [India], November 14: Merck Foundation, the philanthropic arm of Merck KGaA Germany, marks 'World Diabetes Day 2024' together with Africa's First Ladies, Ministries ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...

MilliporeSigmaMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, is the recipient of the 2024 Sustainability Leadership Award in Business Intelligence Group's ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Germany’s Merck KGaA (MRK: DE) was trading 5% lower as Thursday’s trading day neared its end, after the company announced its ...

As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...

Merck KGaA reported a 16.6% decline in contract manufacturing due to an unrepeated Covid-19 contract, though overall life ...

Investing.com -- Shares of Merck KGaA (ETR: MRCG) fell over 4% on Thursday following a mixed reception to its third-quarter ...

Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck KGaA CFO Helene von Roeder discusses the group's third-quarter earnings and its progress with drug trials.